JP2001507696A - グルタチオンの医薬製剤およびその投与方法 - Google Patents

グルタチオンの医薬製剤およびその投与方法

Info

Publication number
JP2001507696A
JP2001507696A JP53020698A JP53020698A JP2001507696A JP 2001507696 A JP2001507696 A JP 2001507696A JP 53020698 A JP53020698 A JP 53020698A JP 53020698 A JP53020698 A JP 53020698A JP 2001507696 A JP2001507696 A JP 2001507696A
Authority
JP
Japan
Prior art keywords
glutathione
mammal
gsh
cells
levels
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP53020698A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001507696A5 (https=
Inventor
デモポウロス，ハリー，ビー．
セリグマン，マイロン，エル．
Original Assignee
アンチオキシダント ファーマシューティカルズ コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21874315&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2001507696(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by アンチオキシダント ファーマシューティカルズ コーポレーション filed Critical アンチオキシダント ファーマシューティカルズ コーポレーション
Publication of JP2001507696A publication Critical patent/JP2001507696A/ja
Publication of JP2001507696A5 publication Critical patent/JP2001507696A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Disinfection or sterilisation of materials or objects, in general; Accessories therefor
    • A61L2/16—Disinfection or sterilisation of materials or objects, in general; Accessories therefor using chemical substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
JP53020698A 1996-12-31 1997-12-31 グルタチオンの医薬製剤およびその投与方法 Pending JP2001507696A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3410196P 1996-12-31 1996-12-31
US60/034,101 1996-12-31
PCT/US1997/023879 WO1998029101A1 (en) 1996-12-31 1997-12-31 Pharmaceutical preparations of glutathione and methods of administration thereof

Publications (2)

Publication Number Publication Date
JP2001507696A true JP2001507696A (ja) 2001-06-12
JP2001507696A5 JP2001507696A5 (https=) 2006-01-05

Family

ID=21874315

Family Applications (1)

Application Number Title Priority Date Filing Date
JP53020698A Pending JP2001507696A (ja) 1996-12-31 1997-12-31 グルタチオンの医薬製剤およびその投与方法

Country Status (8)

Country Link
US (5) US6350467B1 (https=)
EP (1) EP0957901B1 (https=)
JP (1) JP2001507696A (https=)
AT (1) ATE448782T1 (https=)
AU (1) AU5620598A (https=)
CA (2) CA2650204A1 (https=)
DE (1) DE69739663D1 (https=)
WO (1) WO1998029101A1 (https=)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005104852A (ja) * 2003-09-29 2005-04-21 Kyowa Hakko Kogyo Co Ltd モービリウィルス感染症の予防または治療用組成物
WO2009099132A1 (ja) * 2008-02-05 2009-08-13 Kyowa Hakko Bio Co., Ltd. グルタチオンの保存安定性向上方法
JP2010216917A (ja) * 2009-03-16 2010-09-30 Teikyo Univ Ｅｄ評価方法
WO2013122188A1 (ja) * 2012-02-15 2013-08-22 協和発酵バイオ株式会社 血管内皮機能低下の予防または改善剤
WO2014112641A1 (ja) * 2013-01-21 2014-07-24 協和発酵バイオ株式会社 一酸化窒素濃度上昇剤
JP2017534673A (ja) * 2014-09-15 2017-11-24 サウンド・ファーマシューティカルズ・インコーポレイテッド 精神病性障害を治療するための方法および組成物
JP2018517781A (ja) * 2015-06-19 2018-07-05 モレキュラー ディフェンシズ コーポレイション グルタチオン製剤およびその使用方法
JP2022074429A (ja) * 2020-11-04 2022-05-18 三菱商事ライフサイエンス株式会社 グルタチオン機能促進剤及びその方法
WO2022168169A1 (ja) * 2021-02-02 2022-08-11 学校法人日本医科大学 抗ウイルス剤
JP7853071B2 (ja) 2020-11-04 2026-04-28 三菱商事ライフサイエンス株式会社 グルタチオン機能促進剤及びその方法

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744593A (en) * 1996-02-15 1998-04-28 Heska Corporation Parasitic helminth larval thiol specific antioxidant proteins and nucleic acid molecules
US6369106B1 (en) * 1996-12-26 2002-04-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Treatment of ischemic brain injuries with brain targeted anti oxidant compounds
US6896899B2 (en) * 1996-12-31 2005-05-24 Antioxidant Pharmaceuticals Corp. Pharmaceutical preparations of glutathione and methods of administration thereof
WO1999026657A1 (en) * 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibitors of nitric oxide synthase
US20080275104A1 (en) * 1997-11-25 2008-11-06 Musc Foundation For Research Development Methods of treating juvenile type 1 diabetes mellitus
US20040072138A1 (en) * 1997-11-25 2004-04-15 Medical University Of South Carolina Attenuation of ischemia/reperfusion injury
JP4643004B2 (ja) * 1998-01-06 2011-03-02 シーラス コーポレイション 生体材料中の病原体不活性化剤をクエンチするための方法
US20070142267A1 (en) * 1998-11-23 2007-06-21 Novelos Therapeutics, Inc. Methods for production of the oxidized glutathione composite with CIS-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells
US6312734B1 (en) * 1998-11-23 2001-11-06 Novelos Therapeutics, Inc. Methods for production of the oxidized glutathione composite with cis-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells
RU2144374C1 (ru) * 1998-11-23 2000-01-20 Закрытое акционерное общество "ВАМ" Способ получения композита окисленного глутатиона с cis-диаминодихлорплатиной и фармацевтических композиций на его основе, регулирующих метаболизм, пролиферацию, дифференцировку и механизмы апоптоза нормальных и трансформированных клеток
GB2367489B (en) * 2000-07-31 2005-02-09 Mars Inc Use of antioxidants
WO2001012166A2 (en) * 1999-08-17 2001-02-22 University Of Saskatchewan Technologies Inc. Improved treatment for acute physical insult to the central nervous system
US6642274B1 (en) 1999-09-09 2003-11-04 Gary W. Neal Methods and compositions for preventing and treating prostate disorders
EP1214038A2 (en) * 1999-09-09 2002-06-19 Androsolutions, Inc. Methods and compositions for preventing and treating prostate disorders
EP1086695B1 (en) * 1999-09-21 2004-12-22 Enzo Leone Antiviral compositions comprising yohimbine as active principle
AU4085201A (en) * 2000-03-15 2001-09-24 Imperial College Innovations Limited Pharmaceutical composition
WO2001072311A1 (en) * 2000-03-28 2001-10-04 Delorenzo Robert J Inhibition of a novel calcium injury current that forms in neurons during injury prevents neuronal cell death
GB0008689D0 (en) * 2000-04-07 2000-05-31 Nokia Networks Oy A method and system for processing signals
RU2258509C2 (ru) * 2000-04-07 2005-08-20 Санг Геон КИМ Применение олтипраза для профилактики и лечения фиброза и цирроза печени и фармацевтическая композиция, содержащая олтипраз
WO2001085013A2 (en) * 2000-05-09 2001-11-15 Nitromed, Inc. Infrared thermography and methods of use
US6528520B2 (en) * 2000-08-15 2003-03-04 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
US6846831B2 (en) 2000-08-15 2005-01-25 Cpd, Llc Method of treating the syndrome of lipodystrophy
WO2002026223A2 (en) * 2000-09-29 2002-04-04 Board Of Trustees Operating Michigan State University Catecholamine pharmaceutical compositions and methods
US7179791B2 (en) * 2001-01-11 2007-02-20 Duke University Inhibiting GS-FDH to modulate NO bioactivity
US20020169112A1 (en) * 2001-05-08 2002-11-14 Luc Montagnier Combined treatments and methods for treatment of mycoplasma and mycoplasma-like organism infections
US20030096770A1 (en) * 2001-07-11 2003-05-22 Krotz Achim H. Enhancement of the stability of oligonucleotides comprising phosphorothioate linkages by addition of water-soluble antioxidants
WO2003025831A2 (en) * 2001-09-14 2003-03-27 Roke Manor Research Limited Tag and tagging system
US6726809B2 (en) * 2001-09-26 2004-04-27 Albany International Corp. Industrial process fabric
WO2003032908A2 (en) * 2001-10-16 2003-04-24 University Of Kansas Novel prodrugs of n-h bond-containing compounds and methods of making thereof
US20040241256A1 (en) * 2002-12-05 2004-12-02 Seymour Ehrenpreis Medicinal compositions & therapeutic methods
EP1474158B1 (en) * 2001-12-18 2009-10-14 Brassica Foundation for Chemoprotection Research, Inc. Prevention and treatment of oxidative stress disorders by compounds which elevate intracellular levels of glutathione or phase ii detoxification enzymes
US20030194453A1 (en) * 2002-04-15 2003-10-16 Coleman Henry D. Dietary supplement
US20060099239A1 (en) * 2002-04-15 2006-05-11 Coleman Henry D Dietary supplement for promoting removal of heavy metals from the body
US20040213829A1 (en) * 2002-04-15 2004-10-28 Coleman Henry D. Dietary supplement
US20090011048A1 (en) * 2002-04-16 2009-01-08 Coleman Henry D Dietary Supplement For Promoting Removal Of Heavy Metals From The Body
AU2003265321A1 (en) * 2002-05-03 2003-11-17 Luc Montagnier Treatments and methods for the treatment, diagnosis and prophylaxis
US20070065497A1 (en) * 2005-09-20 2007-03-22 Guilford Frederick T Combination and method using EDTA combined with glutathione in the reduced state encapsulated in a liposome to facilitate the method of delivery of the combination as an oral, topical, intraoral or transmucosal, for anti-thrombin effect and for anti-platelet aggregation and measurement of efficacy
US20100316700A1 (en) * 2002-11-07 2010-12-16 Guilford F Timothy Systemic administration of liposomal reduced glutathione for the decorporation of radioactive materials and non-radioactive mercury
WO2004055165A2 (en) * 2002-12-13 2004-07-01 St. Jude Children's Research Hospital Glutathione-s-transferase test for susceptibility to parkinson's
DE10300222A1 (de) * 2003-01-03 2004-07-15 MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH Verwendung von Wirksubstanzen zur Prophylaxe und/oder Therapie von Viruserkrankungen
US20040229815A1 (en) * 2003-01-03 2004-11-18 Nagasawa Herbert T. Methods for reducing oxidative stress in a cell with a sulfhydryl protected glutathione prodrug
US7781539B2 (en) * 2003-02-21 2010-08-24 Metabolix Inc. PHA blends
ATE377060T1 (de) * 2003-02-21 2007-11-15 Metabolix Inc Pha-klebstoffe
US8076060B2 (en) * 2003-08-04 2011-12-13 Emil William Chynn Vaccination and immunotherapy as new therapeutic modalities in the treatment of glaucoma
US20070276024A1 (en) * 2003-10-09 2007-11-29 Inverseon , Inc. Methods for Treating Diseases and Conditions with Inverse Agonists and for Screening for Agents Acting as Inverse Agonists
US20050143300A1 (en) * 2003-10-10 2005-06-30 Ma Jian-Xing Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same
US20050250694A1 (en) * 2003-10-10 2005-11-10 Ma Jian-Xing Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same
BRPI0415409A (pt) * 2003-10-15 2006-12-05 Probiodrug Ag uso de efetuadores de ciclases de glutaminila e glutamato
US20050130897A1 (en) * 2003-12-11 2005-06-16 Ma Jian-Xing Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same
CA2548313A1 (en) * 2003-12-23 2005-07-14 Musc Foundation For Research Development Methods and compositions for the prevention and treatment of inflammatory diseases or conditions
JP2007517126A (ja) * 2003-12-30 2007-06-28 メタボリックス インコーポレイティッド 増核剤
US20050202521A1 (en) * 2004-03-10 2005-09-15 Albert Crum Methods of assessing the need for and the effectiveness of therapy with antioxidants
US8217084B2 (en) * 2004-05-24 2012-07-10 Allium Vitalis Incorporated Medicinal products incorporating bound organosulfur groups
JP5066448B2 (ja) * 2004-09-03 2012-11-07 協和発酵バイオ株式会社 口内炎の予防または治療のための組成物および方法
US20060083724A1 (en) * 2004-10-01 2006-04-20 Hilst Todd W Compositions for the treatment of femal sexual dysfunction
JP5112876B2 (ja) * 2004-11-07 2013-01-09 エフ． ギルフォード ティモシー 還元型グルタチオン経口投与のためのリポソーム処方物
JP2008524123A (ja) * 2004-12-21 2008-07-10 クリティカル ケア コネクションズ インク 治療用栄養組成物又は組合せ、及びそれらの使用方法
CA2595606C (en) * 2005-01-27 2014-12-16 Erimos Pharmaceuticals Llc Oral formulations for delivery of catecholic butanes including ndga compounds
CN101150955B (zh) * 2005-01-27 2013-04-17 埃里莫斯医药品有限公司 递送包括ndga化合物的儿茶酚丁烷的口服制剂
WO2006091610A2 (en) * 2005-02-23 2006-08-31 The Brigham And Women's Hospital, Inc. Inhibitors of enveloped virus infectivity
ES2731298T3 (es) 2005-05-27 2019-11-14 Univ North Carolina Chapel Hill Partículas de liberación de óxido nítrico para agentes terapéuticos de óxido nítrico y aplicaciones biomédicas
US20070004639A1 (en) * 2005-07-01 2007-01-04 Bodybio, Inc. Methods and compositions for treating Parkinson's disease
CA2615319A1 (en) * 2005-07-13 2007-01-18 Al Czap Compositions for oral administration of sustained release glutathione, methods for their production and uses thereof
WO2007033211A2 (en) * 2005-09-12 2007-03-22 The Board Of Regents Of The University Of Texas System Regulation of brain natriuretic peptide and catecholamines for the treatment of cardiovascular diseases
GB2430364A (en) * 2005-09-22 2007-03-28 Carl Ernest Alexander Soft agar bolus for oral drug delivery
US8093207B2 (en) * 2005-12-09 2012-01-10 Unigene Laboratories, Inc. Fast-acting oral peptide pharmaceutical products
EA010926B1 (ru) * 2006-01-20 2008-12-30 Леонид Андреевич Кожемякин Средство для лечения туберкулеза глаз, способ его получения и применения
US20090047340A1 (en) * 2006-03-29 2009-02-19 Guilford F Timothy Liposomal reduced glutathione and 1-arginine, including with other ingredient(s), capable of multipath administration for reversal and prevention of obesity and for mitochondrial biogenesis
CA2664341C (en) 2006-10-05 2018-11-06 Ikaria, Inc. Liquid chalcogenide compositions and methods of manufacturing and using the same
WO2008112887A1 (en) * 2007-03-13 2008-09-18 Musc Foundation For Research Development Methods of treating juvenile type 1 diabetes mellitus
US20080287341A1 (en) * 2007-05-18 2008-11-20 Danyang Chen Treatment of vascular abnormalities using nanoparticles
WO2009003061A1 (en) 2007-06-25 2008-12-31 Fred Hutchinson Cancer Research Center Methods and compositions regarding polychalcogenide compositions
GB0722923D0 (en) * 2007-11-22 2008-01-02 Uhi Millennium Inst Improved anti-platelet compositions
JP5499714B2 (ja) * 2008-02-15 2014-05-21 味の素株式会社 腸管免疫賦活剤
EP2334279A4 (en) * 2008-10-16 2013-03-20 Novan Inc STAIN OXIDE RELEASING PARTICLES FOR MOUTH CARE APPLICATIONS
US8313456B2 (en) * 2009-06-30 2012-11-20 Palo Alto Research Center Incorporated Drug-transfer device, drug-delivery system incorporating the same, methods of fabricating the same, and methods of enabling administration of a drug
CA2771389C (en) 2009-08-21 2019-04-09 Novan, Inc. Wound dressings, methods of using the same and methods of forming the same
WO2011022652A1 (en) 2009-08-21 2011-02-24 Novan, Inc. Topical gels
US20110064828A1 (en) * 2009-09-11 2011-03-17 Novelos Therapeutics, Incorporated Treatment of metastatic tumors and other conditions
BR112012008508A2 (pt) * 2009-10-13 2017-06-13 Novan Inc revestimento de sol-gel, substrato, método para produzir um revestimento de sol-gel
WO2011091807A1 (en) * 2010-01-31 2011-08-04 Abdelrahman Shata Mohammed Shata Anticoagulant and glutathione for treatment of cancer
US8591876B2 (en) 2010-12-15 2013-11-26 Novan, Inc. Methods of decreasing sebum production in the skin
WO2012118829A2 (en) 2011-02-28 2012-09-07 Novan, Inc. Tertiary s-nitrosothiol-modified nitricoxide-releasing xerogels and methods of using the same
US20130323324A1 (en) * 2012-06-01 2013-12-05 Franco Cavaleri Vanadium and vanadyl amino acid complexes
US20140179615A1 (en) * 2012-07-12 2014-06-26 Hainan Weikang Pharmaceutical (Qianshan) Co., Ltd. Glutathione and Acetaminophen Composition and Preparation Method Thereof
CN109054254B (zh) 2012-08-17 2021-02-02 Cj第一制糖株式会社 用于聚合物共混物的生物基橡胶改性剂
ES2659199T3 (es) * 2012-09-28 2018-03-14 Kyowa Hakko Bio Co., Ltd. Agente para aumentar la inmunidad que contiene glutatión
US20140100283A1 (en) * 2012-10-05 2014-04-10 Atlantic Pro Nutrients, Inc. dba XYMOGEN Method to Increase Absorption and Bioavailability of Oral Glutathione
EP3004225A1 (en) 2013-05-30 2016-04-13 Metabolix, Inc. Recyclate blends
PL3639828T3 (pl) 2013-12-24 2022-05-02 Virginia Commonwealth University Zastosowanie utlenowanych siarczanów cholesterolu (ocs) w leczeniu ostrej niewydolności wątroby
MX386702B (es) 2014-02-10 2025-03-19 Fred Hutchinson Cancer Center Tratamiento con halogeno de ataque cardiaco y lesion isquemica.
AU2015330807A1 (en) * 2014-10-09 2017-04-13 Albert Crum Protective metallothionein analog compounds, their compositions and use thereof in the treatment of pathogenic diseases
CA3044804A1 (en) * 2015-11-25 2017-06-01 Molecular Defenses Corporation Pharmaceutical formulations
US10702590B2 (en) * 2016-04-12 2020-07-07 Script Essentials, Llc Compositions and methods for treating thyroid disease
US20180008665A1 (en) * 2016-07-05 2018-01-11 CanTrust LifeScience Corp. Methods of treating and preventing gout and lead nephropathy
AU2017362500B2 (en) 2016-11-17 2024-09-26 Renovion, Inc. Treatment of Respiratory Tract Diseases and Infections with Ascorbic Acid Compositions
BR112020009910A2 (pt) 2017-11-17 2020-11-03 Renovion, Inc. composições de ácido ascórbico estáveis e métodos de usar as mesmas
US10722465B1 (en) 2017-12-08 2020-07-28 Quicksilber Scientific, Inc. Transparent colloidal vitamin supplement
US11344497B1 (en) 2017-12-08 2022-05-31 Quicksilver Scientific, Inc. Mitochondrial performance enhancement nanoemulsion
US11291702B1 (en) 2019-04-15 2022-04-05 Quicksilver Scientific, Inc. Liver activation nanoemulsion, solid binding composition, and toxin excretion enhancement method
EP3733197A1 (en) * 2019-04-30 2020-11-04 Stephen N. Pitcher Anaerobic antioxidant composition
KR20240131358A (ko) 2022-01-04 2024-08-30 레노비온, 아이엔씨. 글루타치온 염을 포함하는 수용액
IT202200007238A1 (it) * 2022-04-12 2023-10-12 Uriach Italy S R L Composizione comprendente n-acetilcisteina, vitamina d e preferibilmente glutatione, suoi usi, e relative composizioni farmaceutiche e nutraceutiche
IT202200007232A1 (it) * 2022-04-12 2023-10-12 Uriach Italy S R L Composizione comprendente acido lipoico, vitamina d e glutatione, suoi usi, e relative composizioni farmaceutiche e nutraceutiche
WO2023199241A1 (en) * 2022-04-12 2023-10-19 URIACH ITALY S.r.l. Composition comprising lipoic acid, vitamin d and glutathione, uses thereof, and pharmaceutical and nutraceutical compositions thereof
IT202200007229A1 (it) * 2022-04-12 2023-10-12 Uriach Italy S R L Composizione comprendente n-acetilcisteina, vitamina d e preferibilmente glutatione, suoi usi, e relative composizioni farmaceutiche e nutraceutiche
CA3255655A1 (en) * 2022-04-12 2023-10-19 URIACH ITALY S.r.l. Composition comprising N-acetylcysteine, vitamin D, and preferably glutathione, associated uses, and related pharmaceutical and nutraceutical compositions
KR102602347B1 (ko) * 2022-05-09 2023-11-15 천현수 위장내 발암성 엔-니트로사민 생성 억제 및 장내 산화질소 생성 촉진용 천연 조성물 및 이의 용도

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1444024A (en) * 1973-07-20 1976-07-28 Passwaterr A Food and feed supplents
FR2461002A1 (fr) 1979-07-13 1981-01-30 Inst Nat Sante Rech Med Procede pour stimuler la croissance des cellules d'epiderme humain et produits faisant application dudit procede
US4381307A (en) 1980-10-31 1983-04-26 Merck & Co., Inc. Soft tertiary amine esters of bio-affecting carboxylic acids
US4477435A (en) 1981-05-19 1984-10-16 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method for regenerating corneal epithelium
US4414212A (en) * 1981-12-10 1983-11-08 Graham J. Naylor Method of treatment of pre-menstrual syndrome
US4454125A (en) 1982-04-22 1984-06-12 Demopoulos Harry B Dry powder formulations having improved flow and compressibility characteristics, and method for the preparation thereof
US4534967A (en) 1982-08-03 1985-08-13 Boston Biomedical Research Institute Cell proliferation inhibitor and method of preparation
US4770877A (en) 1982-08-03 1988-09-13 Boston Biomedical Research Institute Isolation of a high molecular weight aortic endothelial cell growth inhibitor
AU590872B2 (en) 1985-02-26 1989-11-23 Johns Hopkins University, The Neovascularization inhibitors and methods for their production and use
JPS62169723A (ja) * 1986-01-22 1987-07-25 Teisan Seiyaku Kk 徐放化製剤
US6030950A (en) * 1987-07-09 2000-02-29 Ohlenschlaeger; Gerhard Pharmaceutical therapeutic use of glutathione derivative
US5061729A (en) 1988-06-08 1991-10-29 Biogal Gyogyszergyar Pharmaceutical composition and process for preparing the same
IT1231012B (it) 1989-07-27 1991-11-08 Zambon Spa Composizione farmaceutica per uso orale contenente nac.
JP2919870B2 (ja) * 1989-09-29 1999-07-19 千寿製薬株式会社 肝障害抑制剤
US5238683A (en) 1989-11-24 1993-08-24 The United States Of America As Represented By The Department Of Health And Human Services Aerosol preparation of glutathione and a method for augmenting glutathione level in lungs
ES2176179T3 (es) 1991-02-01 2002-12-01 Suntory Ltd Composiciones antibacterianas orales y metodo para la mejora de la absorcion gastrointestinal de los antibioticos de penemo o carbapemo.
US5747459A (en) * 1991-02-04 1998-05-05 Nestec, Ltd. Method for insuring adequate intracellular glutathione in tissue
US5380758A (en) 1991-03-29 1995-01-10 Brigham And Women's Hospital S-nitrosothiols as smooth muscle relaxants and therapeutic uses thereof
EP0746202A4 (en) 1992-01-06 1997-06-25 Health Maintenance Programs COMPOSITION CONTAINING A PHARMACEUTICALLY ACTIVE ANTI-OXIDANT AND METHOD FOR USE IN THE PREVENTION AND TREATMENT OF RESTENOSIS AFTER ANGIOPLASTY
US5204114A (en) 1992-03-30 1993-04-20 Health Maintenance Programs, Inc. Methods of manufacturing high dosage glutathione the tablets and capsules produced thereby
AU661379B2 (en) * 1992-04-23 1995-07-20 Transcend Therapeutics, Inc Method of reducing or preventing toxicity associated with antiretroviral therapy
US6319687B1 (en) 1992-09-24 2001-11-20 The United States Of America As Represented By The Department Of Health And Human Services Pigment epithelium-derived factor: characterization, genomic organization and sequence of PEDF gene
US5840686A (en) 1992-09-24 1998-11-24 The United States Of America As Represented By The Department Of Health And Human Services Pigment epithelium-derived factor: characterization of its novel biological activity and sequences encoding and expressing the protein and methods of use
US5910316A (en) 1992-08-24 1999-06-08 The United States Of America, As Represented By The Department Of Health And Human Services Use of nitric oxide-releasing agents to treat impotency
AU6060694A (en) * 1993-05-10 1994-11-17 Transcend Therapeutics, Inc Method for treating acquired immune deficiency syndrome
US5686436A (en) * 1993-05-13 1997-11-11 Hiv Diagnostics, Inc. Multi-faceted method to repress reproduction of latent viruses in humans and animals
AU4701593A (en) 1993-07-22 1995-02-20 Esseti S.A.S. Laboratorio Chimico Farmaco Biologico Di A. Ievoli & C. Oral pharmaceutical compositions comprising reduced glutathion
US5994339A (en) 1993-10-15 1999-11-30 University Of Alabama At Birmingham Research Foundation Oxidant scavengers
US5985926A (en) 1993-11-01 1999-11-16 Cell Therapeutics, Inc. Method for inhibiting intracellular viral replication
US5679541A (en) 1994-02-14 1997-10-21 California Institute Of Technology Programmed cell death antagonist protein
US5824685A (en) 1995-02-01 1998-10-20 The Johns Hopkins University School Of Medicine Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists
US6015665A (en) 1995-02-13 2000-01-18 The Regents Of The University Of Michigan Method and composition for regulating apoptosis
US5929063A (en) 1995-03-24 1999-07-27 Children's Hospital Medical Center Mercapto and seleno derivatives as inhibitors of nitric oxide synthase
US5674907A (en) 1995-03-24 1997-10-07 Children's Hospital Medical Center Mercapto derivatives as inhibitors of nitric oxide synthase
US5681711A (en) 1995-03-27 1997-10-28 University Of California-Los Angeles Method for promoting apoptosis in mammalian neual cells
US5804376A (en) 1995-05-02 1998-09-08 Incyte Pharmaceuticals, Inc. Pancreas-derived serpin
US5624955A (en) * 1995-05-03 1997-04-29 Regents Of The University Of Minnesota Compounds that enhance the concentration of glutathione in tissues
US5985331A (en) * 1995-05-19 1999-11-16 New York Blood Center, Inc. Methods of use of phthalocyanines to inactivate blood borne parasites
US5932425A (en) 1997-02-18 1999-08-03 Signal Pharmaceuticals, Inc. Compositions and methods for modulating cellular NF-κB activation
US6011067A (en) 1999-06-11 2000-01-04 Thione International, Inc. Antioxidant composition for the treatment of psoriasis and related diseases

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005104852A (ja) * 2003-09-29 2005-04-21 Kyowa Hakko Kogyo Co Ltd モービリウィルス感染症の予防または治療用組成物
WO2009099132A1 (ja) * 2008-02-05 2009-08-13 Kyowa Hakko Bio Co., Ltd. グルタチオンの保存安定性向上方法
JPWO2009099132A1 (ja) * 2008-02-05 2011-05-26 協和発酵バイオ株式会社 グルタチオンの保存安定性向上方法
US9918951B2 (en) 2008-02-05 2018-03-20 Kyowa Hakko Bio Co., Ltd. Method for improving storage stability of glutathione
JP2010216917A (ja) * 2009-03-16 2010-09-30 Teikyo Univ Ｅｄ評価方法
WO2013122188A1 (ja) * 2012-02-15 2013-08-22 協和発酵バイオ株式会社 血管内皮機能低下の予防または改善剤
JPWO2013122188A1 (ja) * 2012-02-15 2015-05-18 協和発酵バイオ株式会社 血管内皮機能低下の予防または改善剤
US11654125B2 (en) 2013-01-21 2023-05-23 Kyowa Hakko Bio Co., Ltd. Agent for elevating nitric oxide concentration
WO2014112641A1 (ja) * 2013-01-21 2014-07-24 協和発酵バイオ株式会社 一酸化窒素濃度上昇剤
JPWO2014112641A1 (ja) * 2013-01-21 2017-01-19 協和発酵バイオ株式会社 一酸化窒素濃度上昇剤
AU2014208077B2 (en) * 2013-01-21 2018-05-24 Kyowa Hakko Bio Co., Ltd. Nitric oxide concentration elevating agent
US12465584B2 (en) 2013-01-21 2025-11-11 Kyowa Hakko Bio Co., Ltd. Agent for elevating nitric oxide concentration
JP2017534673A (ja) * 2014-09-15 2017-11-24 サウンド・ファーマシューティカルズ・インコーポレイテッド 精神病性障害を治療するための方法および組成物
JP2021181473A (ja) * 2014-09-15 2021-11-25 サウンド・ファーマシューティカルズ・インコーポレイテッド 精神病性障害を治療するための方法および組成物
JP2023169413A (ja) * 2014-09-15 2023-11-29 サウンド・ファーマシューティカルズ・インコーポレイテッド 精神病性障害を治療するための方法および組成物
JP2018517781A (ja) * 2015-06-19 2018-07-05 モレキュラー ディフェンシズ コーポレイション グルタチオン製剤およびその使用方法
JP2022074429A (ja) * 2020-11-04 2022-05-18 三菱商事ライフサイエンス株式会社 グルタチオン機能促進剤及びその方法
JP7853071B2 (ja) 2020-11-04 2026-04-28 三菱商事ライフサイエンス株式会社 グルタチオン機能促進剤及びその方法
WO2022168169A1 (ja) * 2021-02-02 2022-08-11 学校法人日本医科大学 抗ウイルス剤

Also Published As

Publication number Publication date
EP0957901B1 (en) 2009-11-18
CA2276183A1 (en) 1998-07-09
US6586404B1 (en) 2003-07-01
US6159500A (en) 2000-12-12
CA2276183C (en) 2009-06-09
EP0957901A4 (en) 2006-04-12
DE69739663D1 (de) 2009-12-31
WO1998029101A1 (en) 1998-07-09
US6423687B1 (en) 2002-07-23
ATE448782T1 (de) 2009-12-15
US6204248B1 (en) 2001-03-20
AU5620598A (en) 1998-07-31
EP0957901A1 (en) 1999-11-24
US6350467B1 (en) 2002-02-26
CA2650204A1 (en) 1998-07-09

Similar Documents

Publication Publication Date Title
JP2001507696A (ja) グルタチオンの医薬製剤およびその投与方法
US6896899B2 (en) Pharmaceutical preparations of glutathione and methods of administration thereof
CN108135964B (zh) 谷胱甘肽制剂和使用方法
US5292773A (en) Treating aids and HIV infection with methionine
US6231894B1 (en) Treatments based on discovery that nitric oxide synthase is a paraquat diaphorase
RU2711913C2 (ru) Лечение пигментной дистрофии сетчатки n-ацетилцистеинамидом
AU2007203159B2 (en) Compositions for therapeutic use comprising a vitamin, a metal salt and insulin or a growth hormone
WO2011145343A1 (ja) ５－アミノレブリン酸又はその誘導体を有効成分とする抗マラリア薬
JP2023511369A (ja) 酸化ストレスの疾患及び傷害の治療のためのプロドラッグ
WO1999024400A1 (en) Probucol esters and uses thereof
RU2096034C1 (ru) Фармацевтическая композиция, индуцирующая биосинтез глутатиона, активность глутатионтрансферазы и оказывающая антитоксическое, радиопротекторное и антигипоксическое действие, и способы лечения, профилактики и защиты с ее использованием
JP2006510714A (ja) 放射線被爆患者の処置方法
JP4580479B2 (ja) 抗ｈｉｖ感染症剤
US6034126A (en) Method for treating glycol poisoning
US5998479A (en) Method of treating adult respiratory syndrome
WO2000038682A1 (en) Anti-hiv infection agents and method for treating hiv infection
JPH04502020A (ja) 腸内鉄吸収性を制御するための経口投与ポルフィリン類
US6291441B1 (en) Method of treating inflammatory bowel disorders
CA2605707A1 (en) Pharmaceutical preparations of glutathione and methods of administration thereof
JP2010184936A (ja) 放射線被爆患者の処置方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20041227

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20041227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050411

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080624

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080922

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081021

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081121

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20081222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081208

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090109

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090714